OtherBASIC SCIENCE INVESTIGATIONS
Direct Procedure for the Production of 211At-Labeled Antibodies with an ε-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugate
Sture Lindegren, Sofia Frost, Tom Bäck, Elin Haglund, Jörgen Elgqvist and Holger Jensen
Journal of Nuclear Medicine September 2008, 49 (9) 1537-1545; DOI: https://doi.org/10.2967/jnumed.107.049833
Sture Lindegren
Sofia Frost
Tom Bäck
Elin Haglund
Jörgen Elgqvist
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 49, Issue 9
September 2008
Direct Procedure for the Production of 211At-Labeled Antibodies with an ε-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugate
Sture Lindegren, Sofia Frost, Tom Bäck, Elin Haglund, Jörgen Elgqvist, Holger Jensen
Journal of Nuclear Medicine Sep 2008, 49 (9) 1537-1545; DOI: 10.2967/jnumed.107.049833
Jump to section
Related Articles
Cited By...
- Harnessing {alpha}-Emitting Radionuclides for Therapy: Radiolabeling Method Review
- Intraperitoneal {alpha}-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations
- Evidence of Local Concentration of {alpha}-Particles from 211At-Labeled Antibodies in Liver Metastasis Tissue
- Model of Intraperitoneal Targeted {alpha}-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes
- Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated {alpha}-Radioimmunotherapy with 211At-MX35-F(ab')2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival
- The Advantage of Antibody Cocktails for Targeted Alpha Therapy Depends on Specific Activity
- Ex Vivo Activity Quantification in Micrometastases at the Cellular Scale Using the {alpha}-Camera Technique
- Intraperitoneal {alpha}-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study